Inventiva (Euronext Paris and NASDAQ: IVA) ('Inventiva” or the 'Company”), a clinical-stage biopharmaceutical company focused ...

Recent findings reveal an unexpected link between oral bacteria and liver scarring through gut barrier damage. Read more.

DelveInsight's Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current ...

New microbiome data show that intestinal bacteria can generate clinically relevant alcohol levels, validating a rare syndrome ...

Find your ideal companion with our complete guide to popular small dog breeds, including temperament, health, and care tips.

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) could be just weeks away from having the first ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful ...

Sanofi’s LEAP2MONO phase 3 study of venglustat to treat type 3 Gaucher disease meets all primary endpoints: Paris Tuesday, February 3, 2026, 13:00 Hrs [IST] Positive results fro ...